Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-06-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
自愿披露关于GB08注射液I期临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about the completion of the first subject enrollment in a Phase I clinical trial for a new drug (GB08 injection). It includes details about the drug, the clinical trial approval by the National Medical Products Administration, and a risk warning. The document explicitly states it does not have a material impact on financial performance and is primarily an operational update about clinical trial progress. It is not a financial report, earnings release, or regulatory certification. The document is short (1067 characters) and serves as a regulatory announcement about clinical trial progress, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like earnings, management changes, or capital updates.
2024-06-17 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于科兴生物制药股份有限公司2024年限制性股票激励计划授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2024 restricted stock incentive plan of 科兴生物制药股份有限公司 (Sino Biopharmaceutical Co., Ltd.). It contains detailed financial advisory opinions, approval procedures, grant conditions, and impact analysis related to the stock incentive plan. The document is comprehensive, over 12,000 characters, and includes detailed financial and procedural information. It is not a simple announcement or a brief summary but a full advisory report. The content focuses on the stock incentive plan and its financial implications, which aligns with a Capital/Financing Update (CAP) category, as it deals with company fundraising, financing activities, or capital structure changes (specifically stock incentives). It is not an Annual Report, Audit Report, or Management Report, nor is it a regulatory filing or announcement. Therefore, the best fit is Capital/Financing Update (CAP).
2024-06-14 Chinese
第二届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of a company, specifically regarding stock incentive plans and the opening of special accounts for raised funds. It includes voting results and references to other announcements published on the stock exchange website. The document does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a regulatory filing or certification letter. The content fits best under Board/Management Information (MANG) as it relates to supervisory board meeting resolutions and approvals concerning management decisions on stock incentives and fund management.
2024-06-14 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2024 second extraordinary general meeting of shareholders. It details the meeting date, attendance, voting results on specific proposals, and legal witness statements confirming the validity of the meeting and votes. The content focuses on the declaration of voting results from the shareholder meeting rather than the meeting materials or the full report of the meeting. The document length is relatively short (2400 characters), and it is clearly a resolution announcement with voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-06-14 Chinese
监事会关于2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期符合归属条件的激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of a company regarding the verification and approval of the vesting conditions for a restricted stock incentive plan. It includes legal references and confirms compliance with relevant laws and company regulations. The content focuses on the approval and verification of stock incentive vesting, which is related to share-based compensation but does not report financial results or detailed financial data. It is not a full annual or interim report, nor an earnings release or management discussion. It is also not a proxy solicitation or voting result announcement. The document is an official announcement related to share-based incentives and their compliance, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a regulatory compliance announcement.
2024-06-14 Chinese
关于向激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of restricted stock to incentive recipients by the company 科兴生物制药股份有限公司. It includes specifics such as the grant date, number of shares, price, eligibility criteria, legal and financial advisor opinions, and detailed terms of the stock incentive plan. The content focuses on the company's equity incentive plan and the related board and supervisory approvals. This type of document is a formal announcement about a share-based compensation plan, which falls under capital or financing activities related to share issuance and equity incentives. It is not a full financial report, audit report, or management report, nor is it a regulatory filing or voting result announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure about a financing-related equity incentive event.
2024-06-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.